CNR Research announced that it attended the IR event 'Korea Investment Week (KIW) 2025' on the 16th and gave a presentation on the topic of 'Strategies for Maximizing Clinical Trial Efficiency'.
Held at the Conrad Seoul Hotel, this year's KIW, under the theme "KOSPI 5000: An Era of Great Transformation," highlighted key industries poised to drive long-term stock market growth. The bio industry's potential, particularly in terms of high added value and potential for technological innovation, drew particular attention, leading to a CRO session.
In a clinical trial environment increasingly regulated, the role of CROs is evolving beyond mere contracting agencies to strategic partners in new drug development. CROs' expertise in comprehensively managing the entire clinical trial process, both domestically and internationally, and facilitating collaboration among stakeholders has become a key factor in the success of new drug development.
Kim Jin-hak, head of C&R Research's US subsidiary who participated as a speaker, said, "As the government's large-scale R&D investment becomes more active, we are quickly securing new growth engines in clinical trials such as candidate substance development and overseas expansion." He explained, "Accordingly, the demand for clinical trials is also expected to continue to increase, so maximizing the efficiency of new drug development is the core competitiveness of the bio industry."
He added, "As CNR Research has led the advancement of clinical trial innovation based on its global network and expertise, we are always ready to leap forward alongside the industry to strengthen our international competitiveness."
- See more related articles
You must be logged in to post a comment.